Premium
Trends in treatment for synchronous colorectal liver metastases: Differences in outcome before and after 2000
Author(s) -
van der Pool Anne E.M.,
Lalmahomed Zarina S.,
de Wilt Johannes H.W.,
Eggermont Alexander M.M.,
Ijzermans Jan N.M.,
Verhoef Cornelis
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21618
Subject(s) - medicine , colorectal cancer , resection , hepatectomy , surgery , stage (stratigraphy) , chemotherapy , overall survival , cancer , gastroenterology , paleontology , biology
Background The traditional treatment for stage IV colorectal cancer has changed from palliative chemotherapy toward an aggressive multimodality approach. In the current study outcome in patients who underwent surgery for synchronous colorectal liver metastases (CLM) in a single center was evaluated. Methods From January 1991 to May 2008 all consecutive patients with synchronous CLM who underwent curative resection of both primary and metastatic disease were included. Date of resection was divided into two groups: date of hepatic resection before and after the year 2000. Results Fifty patients (26%) with synchronous CLM were resected before 2000 and 142 patients (74%) underwent resection after 2000. The estimated 5‐year disease‐free survival before and after 2000 was 9% and 27%, respectively ( P = 0.379). More patients who underwent resection after 2000 were treated with local therapy or underwent resection for intra‐hepatic recurrence (62% vs. 28%, P = 0.033). The estimated 5‐year survival before and after 2000 was 26% and 44%, respectively ( P = 0.001). Conclusion Survival rates in patients with synchronous CLM have been increased in the past decade. The introduction of new chemotherapeutic drugs and a more aggressive treatment approach in patients with liver recurrence were probably major factors in this progress. J. Surg. Oncol. 2010;102:413–418. © 2010 Wiley‐Liss, Inc.